The draft follows an advisory panel's call to ease limits on six peptides and is not yet in effect. DataMeds says its Corexa pharmacy plans to fill eligible prescriptions.
Recap by typeshit. Full story at Stock Titan.
HHS is proposing temporary enforcement priorities and side effect reporting for compounded peptides, with more specifics in Becker's rundown.
Bloomberg reports the Kennedy plan to widen peptide access comes with a side effect reporting rule for compounding pharmacies.
A Facebook user explains that compounded GLP-1 versions were allowed during the branded drug shortage and flags what that means for people still using them.
Sahpra reports about 600 fake medicine complaints this year, and new compounding rules aren't due until early next year, which industry head Stavros Nicolaou calls too late.
The approval covers MASH with F2 to F3 fibrosis, with semaglutide used alongside diet and exercise. A recap of an earlier decision rather than fresh news.
The once-daily tablet covers weight management and type 2 diabetes. Trial patients lost about 5% to 11% of body weight over 72 weeks, per EMA.
Loading…